Revelation Biosciences Inc. to Present at the 34th Annual Roth Conference
Revelation Biosciences Inc. (NASDAQ: REVB) announced that CEO James Rolke will present a corporate overview at the 34th Annual Roth Conference from March 13-15, 2022, at The Ritz Carlton, Laguna Niguel in California. Rolke's presentation is scheduled for March 15, 2022, at 8:00 a.m. PT in Blue – Salon 2. A live webcast will be available on the company's website, and a replay will be accessible for 30 days post-event. Revelation is focused on developing immunologic-based therapies, with its lead candidate REVTx-99 targeting respiratory viral infections.
- None.
- None.
SAN DIEGO, March 08, 2022 (GLOBE NEWSWIRE) -- Revelation Biosciences Inc. (NASDAQ: REVB) (the “Company” or “Revelation”), a clinical-stage life sciences company that is focused on the development of immunologic‑based therapies for the prevention and treatment of disease, announced today that its Chief Executive Officer James Rolke will present a corporate overview in-person at the 34th Annual Roth Conference, which is being held at The Ritz Carlton, Laguna Niguel located in Dana Point, California on March 13-15, 2022.
34th Annual Roth Conference Presentation Details
| Date: | Tuesday, March 15, 2022 | |
| Time: | 8:00 a.m. Pacific Time | |
| Location: | Blue – Salon 2 @ The Ritz Carlton, Laguna Niguel | |
| Webcast: | REVB Webcast Link |
A live webcast of the presentation will also be available in the Investor Relations section of Revelation’s website at https://www.revbiosciences.com. A replay of the presentation will be available on Revelation’s website for 30 days following the event.
Mr. Rolke will be available for one-on-one meetings throughout the conference in person and virtually.
About Revelation Biosciences Inc.
Revelation Biosciences, Inc. is a clinical-stage life sciences company focused on the development of immunologic-based therapies for the prevention and treatment of disease. Revelation has several product candidates in development. REVTx-99, the lead therapeutic candidate, is an intranasal immunomodulator to prevent or treat infections caused by various respiratory viruses such as SARS-CoV-2, including its variants, influenza A and B, parainfluenza, rhinovirus, and RSV. REVTx-99 is also being developed for other indications such as: allergic rhinitis and chronic nasal congestion. REVTx-200 is an intranasal immunomodulator adjunct to be used in combination with an intramuscular vaccination for more complete immunity. REVTx-200 is based on the same technology used in REVTx-99. In addition to Revelation’s therapeutic pipeline, Revelation is also developing REVDx-501, a rapid home use diagnostic that can be used to detect any respiratory viral infection, regardless of virus type or strain, without the need for specialized instrumentation.
For more information on Revelation, please visit www.RevBiosciences.com.
Company Contacts
Sandra Vedrick
Vice President, Investor Relations & Human Resources
Revelation Biosciences Inc.
Email: svedrick@revbiosciences.com
and
Chester Zygmont, III
Chief Financial Officer
Revelation Biosciences Inc.
Email: czygmont@revbiosciences.com
FAQ
What is the date and time of Revelation Biosciences' presentation at the Roth Conference?
Where will the Roth Conference be held?
Will there be a webcast of the presentation by Revelation Biosciences?
What is REVTx-99 developed by Revelation Biosciences?
Is there an opportunity for one-on-one meetings during the Roth Conference?
